https://www.hsph.harvard.edu/news/magazine/winter10assessment/

The following prompt is based on an interview about cost effectiveness research with Professor Weinstein from the Harvard School of Public Health.

Why are some expensive treatments (like lung transplants and pap smears) considered to be bad value and other expensive treatments (like aromatese inhibitors, an expensive class of drugs to treat breast cancer) to be good value?
What can the U.S. do to address the problem of overusing medical care that is not cost effective, and why isnt the U.S. doing this already?